Allarity Therapeutics GAAP EPS of -$0.19 beats by $0.04
Source: SeekingAlpha
2025-11-14 13:34:16 ET
More on Allarity Therapeutics
- Seeking Alpha’s Quant Rating on Allarity Therapeutics
- Historical earnings data for Allarity Therapeutics
- Financial information for Allarity Therapeutics
Read the full article on Seeking Alpha
For further details see:
Allarity Therapeutics GAAP EPS of -$0.19 beats by $0.04
Allarity Therapeutics Inc.
NASDAQ: ALLR
ALLR Trading
-3.07% G/L:
$1.28 Last:
86,155 Volume:
$1.37 Open:
ALLR Latest News
March 06, 2026 08:00:00 am
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
February 18, 2026 08:15:00 am
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
February 03, 2026 08:00:00 am
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
December 31, 2025 08:00:00 am
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
ALLR Stock Data
$14,958,528
16,080,980
0.17%
8
N/A
Biotechnology & Life Sciences
Healthcare
US
Tarpon Springs
